Objectives: to confirm the hypothesis that developing RARγ -selective agonists could yield a new generation of topical acne treatments that would increase safety margins while maintaining the robust efficacy of previous drugs. Materials and Methods: Structural knowledge derived from the X-Ray structure of known RARγ-selective molecule. Design, synthesis and in vitro evaluation of a novel triaryl series of RARγ agonists were performed including structure activity and property relationship.
Results: Results revealed an unique and isotype specific pocket in the RARγ ligand binding domain thus enabling the optimization of a novel triaryl series of RARγ selective agonist for topical administration.
Conclusions: Structural information led to the discovery of Trifarotene, a new RARγ -selective agonist as a potential new generation of topical acne treatments.
